DiaMedica Therapeutics Inc. (DMAC) Guidance & Earnings Results

On 2026-03-31 DiaMedica Therapeutics Inc. reaffirmed guidance: "ReMEDy2 interim analysis completion in 2H 2026; R&D expenses expected to increase moderately; G&A expenses expected to remain steady or increase…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

DMACDiaMedica Therapeutics Inc.Follow DMAC — free

Drug Manufacturers - General · Healthcare

—

Price chart with a free account

Market cap: 470.2M
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 18 Nov, in 25 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
31 Mar 26	Reaffirmed	ReMEDy2 interim analysis completion in 2H 2026; R&D expenses expected to increase moderately; G&A expenses expected to remain steady or increase slightly · full year

DiaMedica Therapeutics Inc. — questions

What guidance did DiaMedica Therapeutics Inc. give?: On 2026-03-31: "ReMEDy2 interim analysis completion in 2H 2026; R&D expenses expected to increase moderately; G&A expenses expected to remain steady or increase slightly"
When does DiaMedica Therapeutics Inc. report earnings?: DiaMedica Therapeutics Inc.'s next earnings report is expected on 2026-11-18.

Every figure on this page comes from DiaMedica Therapeutics Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.